News
SHPHF
0.210
NaN%
--
Sihuan Pharma Launches Share Buyback as Medical Aesthetics Surges
TipRanks · 3d ago
Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong
TipRanks · 4d ago
Sihuan Pharma Uses Share Award Buy to Back Profitable Growth in Aesthetics and Biopharma
TipRanks · 04/21 11:00
Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial
TipRanks · 04/20 09:09
Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib
TipRanks · 04/20 04:08
Sihuan Subsidiary Xuanzhu Wins HKEX Approval for H-Share Full Circulation
TipRanks · 04/17 11:09
Sihuan Unit Wins China Nod for Phase III Anaprazole Trial in H. pylori
TipRanks · 04/15 04:08
Sihuan Subsidiary Xuanzhu Biopharm Clears CSRC Filing for Major H-Share Conversion
TipRanks · 04/12 10:37
Sihuan Pharmaceutical Holdings Group (SHPHF) Gets a Buy from Citic Securities
TipRanks · 04/10 00:56
Sihuan’s Xuanzhu Biopharm Licenses Two Oncology Drugs to Boston Oncology for MENA Markets
TipRanks · 04/09 09:15
Sihuan Pharma Teams With Biocytogen on AI-Driven Obesity Drug R&D
TipRanks · 04/01 10:44
Sihuan Pharmaceutical’s Medical Aesthetics Push Lifts 2025 Revenue and Margins
TipRanks · 03/31 04:14
Sihuan Pharmaceutical Declares Final Cash Dividend for 2025
TipRanks · 03/31 04:10
Sihuan Pharma Subsidiary Xuanzhu Narrows Loss as Revenue Doubles in 2025
TipRanks · 03/30 13:57
Sihuan’s Bireociclib Delivers Strong Phase 3 Breast Cancer Data Published in JAMA Oncology
TipRanks · 03/24 12:12
Sihuan Unit Completes Phase III Enrollment for Novel Reflux Esophagitis Drug in China
TipRanks · 03/22 10:38
Sihuan Pharmaceutical Schedules Board Meeting to Approve 2025 Results and Consider Final Dividend
TipRanks · 03/19 08:50
Sihuan Pharma Subsidiary Xuanzhu Biopharm Added to Hong Kong Stock Connect
TipRanks · 03/08 10:38
Sihuan’s Bireociclib Wins First-Line Breast Cancer Approval, Extending Lead in China
TipRanks · 03/03 09:11
Sihuan Subsidiary Xuanzhu Biopharm Joins Hang Seng Composite Index, Opening Path to Stock Connect
TipRanks · 02/22 10:37
More
Webull provides a variety of real-time SHPHF stock news. You can receive the latest news about Sihuan Pharm Hld through multiple platforms. This information may help you make smarter investment decisions.
About SHPHF
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.